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        Introduction 
  Src is a nonreceptor tyrosine kinase that is hyperactivated in some 
human cancers, often in association with an increase in meta-
static activity (  Lutz et al., 1998  ;   Irby and Yeatman, 2000  ;   Rucci 
et al., 2006  ). In normal cells, Src can be activated by a variety of 
different stimuli, including adhesion to ECM proteins and the 
activation of growth factor receptors (  Roche et al., 1995  ;   Hsia 
et al., 2005  ). Many of these stimuli also result in changes in the 
actin cytoskeleton that require the activity of both Src and Rho 
GTPase family members (  Ridley et al., 1992  ;   Ridley and Hall, 
1992  ). Like other GTPases, Rho family members cycle between 
an active GTP-bound state and an inactive GDP-bound state (  Van 
Aelst and D  ’  Souza-Schorey, 1997  ;   Kjoller and Hall, 1999  ). GTP 
loading is facilitated by guanine nucleotide exchange factors 
(GEFs), and GTP hydrolysis can be catalyzed by GTPase acti-
vating proteins (GAPs;   Lamarche and Hall, 1994  ;   Cherfi  ls and 
Chardin, 1999  ). In fi  broblasts, Rho activation leads to an increase 
in actomyosin contractility and the formation of stress fi  bers 
(  Ridley and Hall, 1992  ;   Amano et al., 1996, 1998  ). The activation 
of Rac and CDC42, two other members of the Rho family, leads 
to membrane ruffl  ing and the formation of fi  lopodia, respec-
tively (  Ridley et al., 1992  ;   Kozma et al., 1995  ). 
  Transformation of fi  broblasts by retroviral Src (v-Src) or 
mutationally activated Src (SrcY527F) represents a model sys-
tem for studying the mechanism by which Src activity leads to 
cell transformation and invasion. During tumor progression, 
cells gain the ability to invade other tissues, a process involving 
the coordination of cell migration and the secretion of extra-
cellular proteases. Until recently, it was thought that the activation 
of Src led to an inhibition of Rho activity and that this decrease 
in Rho activity was responsible for the loss of stress fi  bers ob-
served in Src-transformed cells. However, although expression 
of constitutively active Rho can suppress morphological trans-
formation by Src, levels of Rho-GTP do not decrease in Src-
transformed cells (  Mayer et al., 1999  ;   Pawlak and Helfman, 
2002  ;   Berdeaux et al., 2004  ). In addition, cycling of Rho activa-
tion is required for migration of fi  broblasts, a process controlled 
by Src (  Timpson et al., 2001  ). Furthermore, active Rho is required 
for Src-induced formation of podosomes, specialized adhesive 
structures that cause localized degradation of ECM proteins 
(  Berdeaux et al., 2004  ). 
  Extracellular signal  –  regulated kinase 5 (ERK5), also known 
as Big-MAPK1 (BMK1), is a member of the MAPK family of 
  I
ncreased Src activity, often associated with tumorigene-
sis, leads to the formation of invasive adhesions termed 
podosomes. Podosome formation requires the function 
of Rho family guanosine triphosphatases and reorgani-
zation of the actin cytoskeleton. In addition, Src induces 
changes in gene expression required for transformation, 
in part by activating mitogen-activated protein kinase 
(MAPK) signaling pathways. We sought to determine 
whether MAPK signaling regulates podosome formation. 
Unlike extracellular signal –  regulated kinase 1/2 (ERK1/2), 
ERK5 is constitutively activated in Src-transformed ﬁ  bro-
blasts. ERK5-deﬁ  cient cells expressing v-Src exhibited 
  increased RhoA activation and signaling, which lead to 
cellular retraction and an inability to form podosomes 
or induce invasion. Addition of the Rho-kinase inhibitor 
Y27632 to ERK5-deﬁ  cient cells expressing v-Src led to 
  cellular extension and restored podosome formation. In Src-
transformed cells, ERK5 induced the expression of a Rho 
GTPase-activating protein (RhoGAP), RhoGAP7/DLC-1, 
via activation of the transcription factor myocyte enhanc-
ing factor 2C, and RhoGAP7 expression restored podo-
some formation in ERK5-deﬁ  cient cells. We conclude that 
ERK5 promotes Src-induced podosome formation by in-
ducing RhoGAP7 and thereby limiting Rho activation.
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formation, which indicates that MEK activity is required for 
Src-induced podosome formation (  Fig. 1 C  ). Rosettes were lost 
after a 6-h treatment with U0126, and a loss of punctate actin 
structures was observed after 8 h (  Fig. 1 C  , top right). Rosette 
structures began to reappear 8 h after removal of U0126 (not 
depicted), and by 24 h, rosette structures and cell morphology 
were identical to those of untreated cells (  Fig. 1 D  , untreated). 
The delay in podosome formation after the removal of the 
UO126 suggested that protein synthesis is necessary for the 
  reformation of podosomes after MEK inhibition. We tested this 
using cycloheximide to block de novo protein synthesis. Cells 
treated with cycloheximide (10   μ  g/ml) just before removal of 
U0126 did not reform podosomes but instead appeared more 
rounded, with strong cortical F-actin staining (  Fig. 1 D  , left), 
which indicates that reformation of podosomes in these cells re-
quired de novo protein synthesis. Similar results were obtained 
with another MEK inhibitor, PD 98059 (unpublished data). We con-
clude that activation of Src leads to ERK5 activation and that 
MEK activity and de novo protein synthesis are required for 
  podosome formation in Src-transformed cells. 
  ERK5 is required for podosome formation 
in Src-transformed cells 
  To determine whether ERK5 was required for Src-induced podo-
some formation, we expressed a temperature-sensitive mutant 
of v-Src, ts-UP1, in ERK5 null mouse embryonic fi  broblast 
(ERK5   /   ) cells expressing an empty vector and in ERK5   /   
cells reexpressing ERK5, hereinafter referred to as ERK5-FL 
cells (ERK5-null mouse embryonic fi  broblasts stably expressing 
wild-type ERK5 cDNA). Pools of stable transfectants were 
grown for 24 h at 40  °  C to inhibit Src activity and then either kept 
at 40  °  C or shifted to the permissive temperature for another 24 h. 
Podosomes were visualized as punctate structures containing 
both F-actin and cortactin. Stable expression of v-Src in ERK5-
FL cells caused formation of podosomes in almost 60% of the 
cells ( Figs. 2  and  3 B ). However, ERK5  /   cells stably express-
ing v-Src did not form podosomes and appeared rounded with 
strong cortical F-actin staining at the permissive temperature 
( Fig. 2 ). The punctate actin-rich structures detected in the ERK5-
FL  –  transformed cells were also stained by an antibody against 
the podosome component FISH/Tks5 and by an antibody that 
recognizes tyrosine-phosphorylated proteins (  Fig. 3 A  ), which 
confi  rms that these structures are podosomes. The appearance 
of some podosomes in ERK5-FL cells expressing ts-UP1 and 
grown at 40  °  C (  Fig. 3 B  ) may be attributed to the leakiness of the 
ts-UP1 mutant, which retains residual kinase activity even at the 
nonpermissive temperature. We conclude that ERK5 is required 
for podosome formation in Src-transformed cells. 
 Expression of ts-UP1 led to an increase in tyrosine phosphory-
lation independent of ERK5 expression (  Fig. 3 C  ). However, 
we observed that ERK5   /    cells expressing v-Src had higher 
levels of activated ERK1/2 than ERK5-FL cells expressing v-Src 
( Fig.  3  D ).  In  addition, activation of temperature-sensitive v-Src 
(ts-v-Src) caused an increase in Fra-1 levels in both ERK5   /   
and ERK5-FL cells expressing ts-v-Src ( Fig. 3 D ). Thus, increased 
ERK1/2 activation and the expression of Fra-1 are not suffi  cient to 
induce podosome formation in the absence of ERK5. 
serine/threonine protein kinases and can only be activated by 
Map and ERK kinase 5 (MEK5;   Wang et al., 2005  ). It is unique 
in that it contains a C-terminal transactivation domain, allowing 
for a more direct role in the expression of gene targets (  Kasler 
et al., 2000  ;   Sohn et al., 2005  ). In addition, ERK5 activates 
many downstream proteins including members of the myocyte 
enhancing factor 2 (MEF2) family of transcription factors, sig-
nal transducers and activators of transcription (STATs), Myc, 
sap1a, serum-response element binding proteins (SREBPs), and 
the ribosomal protein S6 kinase (p90RSK;   Kato et al., 1997  ; 
 English et al., 1998 ;  Kamakura et al., 1999 ;  Pearson et al., 2001 ). 
Src has been shown to mediate ERK5 activation in response to 
a variety of different stimuli, including epidermal growth fac-
tor receptor activation, cellular exposure to asbestos, hypoxia-
inducing conditions, and exposure to reactive oxygen species (  Abe 
et al., 1997  ;   Kato et al., 1998  ;   Kamakura et al., 1999  ;   Scapoli 
et al., 2004  ). ERK5 was required for focus formation in v-Src  –
  transformed cells, and activated Src induced ERK5 nuclear 
translocation and MEF2-dependent gene expression (  Barros and 
Marshall, 2005  ). Finally, activation of ERK5 in fi  broblasts can 
lead to changes in the actin cytoskeleton, including a loss of 
stress fi  bers (  Barros and Marshall, 2005  ). 
  We show here that ERK5 is constitutively activated in fi  bro-
blasts transformed by mutationally activated c-Src or v-Src. ERK5 
was found to be required for podosome formation and for the 
invasive properties of cells transformed by constitutively active 
Src. We found that in Src-transformed cells, ERK5 induces a 
RhoGAP, RhoGAP7/DLC-1, thus limiting Rho activation and 
Rho-dependent signaling and allowing the formation of podo-
somes and the generation of an invasive phenotype. 
  Results 
  ERK5 is activated in Src-transformed cells 
  NIH3T3 cells transformed by v-Src form punctate podosomes, 
whereas NIH3T3 cells transformed by a mutationally activated 
form of c-Src (Y527F) form large podosome rosettes (  Tarone 
et al., 1985  ;   Lock et al., 1998  ). Both structures are associated 
with cellular invasion. ERK5 activation was increased in NIH3T3 
cells expressing either SrcY527F or v-Src (  Fig. 1 A  ). Activation 
of Src can lead to increased ERK1/2 activity (  Maudsley et al., 
2000  ). However, unlike the activation of ERK5, which is con-
stitutive in Src-transformed cells (  Fig. 1 A  ), the activation of 
ERK1/2 after Src activation is transient. Indeed, the levels of 
ERK1/2 activity were lower in the c-Src (Y527F)  –  transformed 
cells than in the untransformed parental cells (  Fig. 1 A  ). Although 
the level of ERK1/2 activity is decreased, a downstream target 
of MAPK signaling, Fra-1, is constitutively induced in c-Src 
(Y527F)  –  transformed cells (  Fig. 1 B  ). 
  To examine the effects of inhibition of MAPK signaling 
on Src-induced podosome formation, we initially used the c-Src 
(Y527F)  –  transformed NIH3T3 cells because of their ability to 
form easily visualized rosettes of podosomes. Treatment of Src-
transformed cells with the MEK inhibitor U0126 inhibited both 
ERK1/2 and ERK5 activation and decreased Fra-1 protein levels 
(  Fig. 1 B  ). Furthermore, treatment of c-Src (Y527F)  –  transformed 
NIH3T3 cells with U0126 for 24 h prevented rosette podosome 1197  ERK5 AND PODOSOME FORMATION   • Schramp et al. 
We monitored protease secretion by an in situ zymography 
  assay in which cells were plated onto an Oregon green  –  gelatin 
substrate, and protease secretion was detected by the appearance 
of nonfl  uorescent holes beneath the cell. We saw the appearance 
  The invasive phenotype associated with Src 
transformation requires ERK5 
  Proteases secreted locally at podosomes degrade the ECM, al-
lowing for cellular invasion (  Linder and Aepfelbacher, 2003  ). 
  Figure 1.       MAPK signaling is required for Src induced podosome formation.   (A) NIH3T3 cells stably expressing an empty vector or SrcY527F were analyzed for 
ERK5, ERK1/2, and Src activity using anti  –  phospho-ERK5, anti  –  phospho-ERK1/2, or anti-phospho-tyrosine antibodies, respectively. Parental 3T3 cells expressing 
an empty vector or v-Src were analyzed similarly. (B) Whole cell lysates of NIH3T3 cells expressing empty vector (lanes 1  –  2) or c-SrcY527F (lanes 3  –  4) were 
treated with DMSO (lanes 1 and 3) or 25   μ  M U0126 (lanes 2 and 4) for 24 h and subjected to immunoblot analysis against the proteins indicated. (C) SrcY527F 
cells were treated with DMSO (top left) or 25   μ  M U0126 for the times indicated. Cells were ﬁ  xed and stained for F-actin using rhodamine-phalloidin. Shown 
is a graphical representation of the percentage of cells containing rosettes, punctate actin structures, or no podosome-like structures at the indicated times after 
addition of U0126. All images were taken with a 40  ×   objective lens. Bar, 20   μ  m. (D) Src527F cells were treated with U0126 for 24 h and then removed from 
the MEK inhibitor to monitor podosome reformation. 30 min before removing the inhibitor, 10   μ  g/ml cycloheximide was added where indicated. Cells were 
washed to remove the inhibitor, and fresh medium with or without cycloheximide was added as indicated. 24 h after removal of U0126, cells were ﬁ  xed in 4% 
paraformaldehyde and stained for F-actin using rhodamine-phalloidin. Shown are two representative images. All images were taken with a 40  ×   objective.     JCB • VOLUME 181 • NUMBER 7 • 2008  1198 
two cell lines were only minimally different (  Fig. 4 C  , bottom). 
In contrast, there was a drastic reduction in the ability of 
ERK5   /    cells stably expressing ts-v-Src to invade through 
the Matrigel (  Fig. 4 C  , top). This suggests that the inability of 
ERK5   /    ts-v-Src  –  expressing cells to assemble podosomes 
blocks the invasive phenotype in Src-transformed cells. 
  Loss of ERK5 in v-Src  –  transformed cells 
elevates Rho-GTP loading and stimulates 
Rho-mediated signaling pathways 
  The rounded appearance and strong cortical F-actin staining 
in the ERK5   /    ts-UP1 cells (  Fig. 2  ) are reminiscent of the 
of nonfl  uorescent holes beneath   >  40% of the ERK5-FL ts-v-Src 
cells, which corresponds to the presence of punctate F-actin 
structures in these same cells (  Fig. 4 A  , bottom; and   Fig. 4 B  ). 
However,   <  2% of ERK5   /    cells expressing ts-v-Src induced 
any matrix degradation (  Fig. 4 A  , top; and   Fig. 4 B  ). This de-
crease in protease secretion resulting from ERK5 defi  ciency 
correlates with the loss of podosome formation in these cells. 
To investigate the effects of ERK5 defi  ciency on the ability of 
Src-transformed cells to invade in vitro, we examined the ability 
of ERK5   /    or ERK5-FL cells expressing ts-UP1 to migrate 
across transwell fi  lters or to invade through transwell fi  lters 
coated with a layer of Matrigel. The migratory properties of the 
  Figure 2.       ERK5    /     cells expressing ts-v-Src fail to form podosomes and become rounded with increased F-actin at the cell membrane.   ERK5    /     and 
ERK5-FL cells stably transfected with ts-UP1 were grown at 40  °  C for 24 h and then kept at 40  °  C (top) or shifted to 37  °  C (bottom) for 24 h. Cells were ﬁ  xed 
in 4% paraformaldehyde and then stained with rhodamine-phalloidin, anti-cortactin antibody, and DAPI. Arrows indicate cells with podosomes. All images 
were taken with a 63  ×   objective. Bars, 20   μ  m.     1199  ERK5 AND PODOSOME FORMATION   • Schramp et al. 
phenotype that results from expression of activated Rho, and led 
us to hypothesize that the loss of ERK5 affects signaling by 
Rho. To test this, we measured the level of GTP-bound RhoA, 
Rac1, and CDC42 by affi  nity precipitation with the Rho family  –
  Figure 3.       ERK5    /     cells expressing ts-v-Src have increased ERK1/2 activation.   (A) Cells were treated as in   Fig. 2   but stained with anti-phosphotyrosine 
(top) or anti-Tks5/FISH (bottom), rhodamine-phalloidin, and DAPI. All images were taken with a 63  ×   objective. Arrows indicate cells with podosomes. Bars, 
20   μ  m. (B) Graphical representation of the mean percentage of cells displaying podosomes over three experiments. Error bars represent SD. (C) ERK5    /     
and ERK5-FL cells expressing ts-UP1 or not were monitored for Src activation by immunoblotting cellular proteins with anti-phosphotyrosine antibody. 
(D) ERK5-null ﬁ  broblasts and ﬁ  broblasts reexpressing ERK5 were stably transfected with a temperature-sensitive mutant of v-Src (ts-UP1). Cells were grown 
for 24 h at 40  °  C and then kept at 40  °   or shifted to the permissive temperature of 37  °   for 24 h. ERK5 and ERK1/2 were assayed by immunoblotting with 
anti-phosphoepitope antibodies.     
 specifi  c binding domains of Rhotekin or Pak fused to glutathione  –
  S-transferase (GST). We detected no signifi  cant difference in 
Rac-GTP or CDC42-GTP between v-Src  –  expressing cells with 
or without ERK5 (unpublished data). However, the level of JCB • VOLUME 181 • NUMBER 7 • 2008  1200 
vation of MLC kinase (MLCK). In parallel with the increase in 
Rho-GTP loading, the phosphorylation of MLC was increased 
in ERK5   /    ts-v-Src cells over the level observed in ERK5-
FL ts-v-Src cells (  Fig. 5 C  , left). Thus, we conclude that the loss 
of ERK5 in Src-transformed cells causes a hyperelevation in the 
level of GTP-bound Rho, increased Rho-mediated cellular con-
tractility, and the appearance of rounded cells. 
  Hyperactivation of Rho-mediated signaling 
pathways negatively regulates podosome 
formation in Src-transformed cells 
  We used a chemical inhibitor of ROCK (Y-27632) to determine 
if blocking Rho-mediated contractility could restore podosome 
Rho-GTP in ERK5   /    ts-UP1 cells grown at 37  °  C was increased 
dramatically over the level in the ERK5-FL ts-UP1 cells (  Fig. 5 A  ). 
Additionally, activation of ts-v-Src caused an increase in Rho-
GTP levels in both cell lines, which is consistent with the idea 
that Src can lead to Rho activation. In contrast, loss of ERK5 
did not signifi  cantly increase the level of Rho-GTP in cells that 
did not express v-Src (  Fig. 5 B  ). We conclude that Src induces 
Rho-GTP loading and that the activity of ERK5 limits the ex-
tent of this activation. 
  GTP binding to Rho can lead to the activation of down-
stream effectors such as Rho kinase (ROCK). ROCK activation 
in turn leads to an increase in the phosphorylation of myosin 
light chain (MLC) either by direct phosphorylation or via acti-
  Figure 4.       Loss of ERK5 inhibits v-Src  –  induced ECM degradation and invasiveness.   (A) ERK5    /     and ERK5-FL cells stably transfected with ts-UP1 were 
plated onto coverslips coated with Oregon green  –  gelatin. 3 h after plating, cells were ﬁ  xed and stained with rhodamine-phalloidin and DAPI (arrows 
indicate cells degrading Oregon green  –  gelatin). All images were taken with a 63  ×   objective. Bars, 20   μ  m. (B) At right is a graphical representation of the 
mean percentage of cells counted that were degrading the gelatin matrix over four experiments. (C) ERK5    /     and ERK5-FL cells stably transfected with 
ts-UP1 were grown on uncoated transwell ﬁ  lters alone (bottom) to measure migration or on transwell ﬁ  lters coated with Matrigel (top) to measure invasive-
ness. Cells that had invaded through the ﬁ  lter were counted. Shown is a graphical representation of the fraction of ERK5    /     ts-UP1 cells counted relative 
to the number of ERK5-FL ts-UP1 cells that were counted. Error bars represent SD.     1201  ERK5 AND PODOSOME FORMATION   • Schramp et al. 
pression of DN-Rho in ERK5-FL cells expressing ts-v-Src 
had little effect on cell spreading (  Fig. 7 D  , right). These fi  nd-
ings provide further evidence for the conclusion that the cel-
lular rounding phenotype observed in ERK5-defi  cient cells 
is caused by hyperactivation of Rho. In both cell lines, expres-
sion of DN-Rho suppressed podosome formation, as very few 
GFP-positive cells had punctate F-actin staining (  Fig. 7 D  ), 
which is consistent with our previous fi  nding (  Berdeaux et al., 
2004  ) that Rho function is required for Src-induced podo-
some formation. We conclude that suppression of the ROCK-
dependent contractility in ERK5   /    ts-v-Src cells restores 
cell spreading and podosome formation. A possible explana-
tion for the failure of DN-Rho to restore podosome formation 
is that some other aspect of Rho function other than ROCK-
dependent actomyosin contractility is required for podosome 
assembly (see Discussion). 
  Expression of a constitutive active mutant 
of MEF2C limits Rho activation and 
restores podosome formation in ERK5    /     
cells expressing ts-v-Src 
  The MEF2 family of transcription factors, especially MEF2C 
and MEF2D, has been shown to be activated by ERK5 (  Kato 
et al., 2000  ). Expression of ts-UP1 caused an increase in the 
  activity of a MEF2 transcriptional reporter in ERK5-FL cells but 
not in ERK5   /    cells (  Fig. 8 A  ), which indicates that Src acti-
vates MEF2-mediated transcriptional changes and that this acti-
vation is dependent on ERK5. 
  To determine whether MEF2C function could rescue the 
defect in podosome formation resulting from ERK5 defi  ciency, 
we introduced a constitutively active mutant of MEF2C that 
formation in ERK5   /    ts-v-Src cells. Treatment of ERK5   /   
or ERK5-FL cells stably expressing ts-v-Src with 20   μ  M 
Y-27632 blocked MLC phosphorylation ( Fig. 5 C , right). Treatment 
of ERK5   /    cells expressing ts-v-Src with 20   μ  M Y-27632 
for 24 h resulted in cell spreading (  Fig. 6  , middle ERK5   /   
panels) and restored podosome formation in almost 35% of the 
cells (  Fig. 6  , bottom ERK5   /    panels). Treatment of ERK5-
FL ts-v-Src cells with Y-27632 had little effect on cell spread-
ing or podosome formation (  Fig. 6  ), which is consistent with 
previous fi  ndings that this inhibitor does not block podosome 
assembly (  Berdeaux et al., 2004  ). Treatment of ERK5   /    or 
ERK5-FL cells stably expressing ts-v-Src with 10   μ  M blebbi-
statin, an inhibitor of actomyosin-based contractility (  Kovacs 
et al., 2004  ), for 24 h had a similar effect on cell morphology 
and podosome formation as treatment with Y-27632 (unpub-
lished data). These findings suggest that hyperactivation of 
Rho  –  ROCK signaling pathways blocks cell spreading and podo-
some formation. To validate this conclusion, we expressed a 
myc-tagged constitutively active mutant of ROCK (CA-ROCK; 
  Ishizaki et al., 1997  ) in Src527F-transformed 3T3 cells. Ex-
pression of CA-ROCK caused cellular rounding and a   >  60% 
reduction in the number of cells forming podosomes (  Fig. 7, 
A and C  ). 
  To examine the effects of blocking Rho activation on 
cell spreading and podosome formation in ERK5-defi  cient cells 
expressing ts-UP1, we expressed a dominant-negative mutant 
of Rho (RhoS19N) in ERK5   /    and ERK5-FL cells express-
ing ts-UP1. A cotransfected GFP construct was used to identify 
transfected cells. Expression of DN-Rho caused the ERK5   /   
cells expressing ts-v-Src to become more spread as compared 
with cells expressing GFP alone (  Fig. 7 D  , left), whereas ex-
  Figure 5.       Activation of RhoA and phosphorylation of MLC 
by v-Src are elevated in ERK5    /     cells  . (A) Afﬁ  nity pull-down 
assays were used to determine the levels of Rho activation. 
ERK5    /     and ERK5-FL cells expressing ts-UP1 were grown 
at 40  °  C for 24 h and then shifted to 37  °  C for 24 h or kept 
at 40  °  C. Cell lysates adjusted to equal protein concentra-
tions were incubated with GST-RBD as described in Materials 
and methods. The left and right portions of this blot are from 
separate experiments. (B) ERK5    /     and ERK5-FL cells were 
grown at 40  °  C for 24 h and then shifted to 37  °  C for 24 h. 
Rho activity was measured as described in A. (C) ERK5    /     
and ERK5-FL cells stably expressing ts-UP1 were grown as in A. 
At the time of the shift to the permissive temperature, cells 
were treated with 20   μ  M Y-27632 where indicated. 24 h 
later, cells were lysed and whole cell lysates adjusted to equal 
protein concentrations were used to monitor MLC phosphory-
lation by immunoblot analysis.     JCB • VOLUME 181 • NUMBER 7 • 2008  1202 
  Figure 6.       Treatment of ERK5    /     v-src  –  expressing cells with the ROCK inhibitor Y-27632 results in cell spreading and podosome formation  . ERK5    /     
and ERK5-FL cells stably transfected with ts-UP1 were treated as in   Fig. 5 D  . Cells were ﬁ  xed and stained using rhodamine-phalloidin, anti-cortactin anti-
body, and DAPI (arrows indicate cells with podosomes). For the ERK5    /     ts-v-Src cells treated with the inhibitor, two images are shown. All images were 
taken with a 63  ×   objective. Bars, 20   μ  m.     
contains the DNA-binding and protein  –  protein interaction do-
mains of MEF2C fused to the transactivation domain of the viral 
protein VP16 into ERK5   /    cells stably expressing ts-v-Src. 
Stable expression of the fusion protein consisting of amino 
  acids 1  –  117 of MEF2C fused to the transactivation domain of 
VP-16 (MEF2C-VP16) resulted in an increase in cell spreading 1203  ERK5 AND PODOSOME FORMATION   • Schramp et al. 
  RhoGAP7/DLC-1 is preferentially 
expressed in ERK5-FL ts-v-Src cells and 
is required for Src-induced podosome 
formation 
  The observations described above suggested that v-Src causes 
ERK5-dependent gene expression and that some of the targets of 
this pathway act to limit Rho activation. Therefore, we performed 
microarray analyses on ERK5   /    and ERK5-FL cells express-
ing ts-v-Src to identify genes that might play a role in control-
ling Rho activation. These data indicated that RhoGAP7, also 
known as deleted in liver cancer 1 (DLC-1), was preferentially 
in the ERK5   /    cells expressing ts-v-Src (  Fig. 8 B  ). Further-
more, expression of MEF2C-VP16 resulted in an almost four-
fold increase in the number of podosome-bearing cells (  Fig. 8, 
B and C  ). Moreover, there was a dramatic decrease in the level 
of Rho-GTP in the cells expressing MEF2C-VP16 (  Fig. 8 D  ). 
We conclude that Src activation leads to ERK5-mediated MEF2 
family transcription factor activation, and that the activation of 
MEF2C acts to limit Rho-GTP loading, allowing the formation 
of podosomes. However, we cannot exclude the possibility that 
there may be other ERK5-dependent pathways that also act to 
limit Rho activation. 
  Figure 7.       Expression of a constitutively active mutant of ROCK inhibits podosome formation in Src527F-transformed cells, whereas expression of DN-
RhoA in ERK5    /     ts-v-Src cells rescues cell spreading but blocks podosome formation.   (A) Src527F-transformed NIH3T3 cells were transfected with 
CA-ROCK-myc and plated onto glass coverslips. 24 h after plating, cells were ﬁ  xed and stained with rhodamine-phalloidin and anti-myc. Arrows indicate 
cells expressing CA-ROCK-myc. (B) Whole cell extracts of Src527F-transformed cells transfected with an empty vector or CA-ROCK-myc were subjected to 
immunoblot analysis with an anti-myc antibody. (C) Shown is a graphical representation of the mean percentage of transfected cells showing podosomes 
(  n   = 3). Error bars represent SD. (D) ERK5    /     and ERK5-FL cells stably transfected with ts-UP1 were transfected with pGEX-GFP alone or with DN-RhoA 
and 10-fold less pGEX-GFP. Cells were plated on glass coverslips for 24 h, ﬁ  xed, and stained for F-actin using rhodamine-phalloidin and DAPI. Arrows in 
F-actin  –  stained pictures indicate GFP-positive cells. All images were taken with a 63  ×   objective. Bars, 20   μ  m.     JCB • VOLUME 181 • NUMBER 7 • 2008  1204 
  Figure 8.       Expression of MEF2C-VP16 induces podosome formation and inhibits Rho hyperactivation in ERK5    /     cells expressing v-Src.   (A) ERK5    /    , 
ERK5-FL, and ERK5    /     and ERK5-FL cells expressing v-Src were cotransfected with a MEF2C-CAT reporter gene and a vector expressing GFP as a trans-
fection efﬁ  ciency control. 48 h after transfection, cells were harvested and CAT activity was assayed. Numbers represent the fold increase in CAT activity 
normalized to GFP levels over the level observed in ERK5    /     cells. Shown is a graphical representation of the increase in CAT activity.   n   = 3 (P   <   0.05 
for ERK5-FL v-src cells compared with all other lines). (B) ERK5    /     ts-UP1 cells were stably transfected with pCDNA3.1-zeo or pCDNA3.1-zeo contain-
ing a constitutively active mutant of MEF2C, MEF2C-VP16. Cells were grown on glass coverslips for 24 h, ﬁ  xed, and stained using rhodamine-phalloidin, 
anti-cortactin, and DAPI. All images were taken with a 63  ×   objective. Bars, 20   μ  m. (C) Shown is a graphical representation of the percentage of cells 
that had podosomes (  n   = 3). Error bars represent SD. (D) ERK5    /     ts-UP1 cells stably transfected with an empty vector or with a vector expressing 1205  ERK5 AND PODOSOME FORMATION   • Schramp et al. 
and the most prominent phenotype of Src-defi  cient mice is osteo-
petrosis, a disease caused by a defect in osteoclast podosome 
formation. Thus, the pathways through which Src signals to in-
duce podosome formation and cellular invasion are of consider-
able interest. 
  The results described here indicate that the small GTPase 
Rho is a key regulator of Src-induced podosome formation. 
  Because the activation of Rho is known to induce the formation 
of stress fi  bers, it was previously thought that the disappearance 
of these structures in Src-transformed cells was caused by a 
decrease in the level of Rho activation. Consistent with this 
hypothesis, Src has been shown to phosphorylate and possibly 
activate p190RhoGAP (  Fincham et al., 1999  ). However, we and 
others have shown that there is no reduction in the overall level 
of Rho-GTP in fi  broblasts transformed by SrcY527F or v-Src 
(  Pawlak and Helfman, 2002  ;   Berdeaux et al., 2004  ). Further-
more, we observe a dramatic increase in Rho-GTP levels in 
ERK5   /    cells expressing v-Src, which indicates that Src can 
activate Rho-GTP loading. The results described here lead to 
the model shown in   Fig. 10  . In this model, Src induces Rho 
  activation, but this activation is limited by ERK5-dependent 
induction of RhoGAP7/DLC-1. Thus, in the absence of ERK5, 
Src induces hyperactivation of Rho. Rho, in turn, is necessary 
for podosome formation, as we and others have previously shown 
(  Chellaiah et al., 2000  ;   Berdeaux et al., 2004  ), but hyper-
activa tion  of Rho leads to elevated actomyosin contractility 
that blocks cell spreading and podosome formation. Thus, the rela-
tionship between Src, Rho, and podosome formation is complex. 
We propose a model (  Fig. 10  ) in which Src promotes both Rho 
activation and Rho inactivation, and where Rho, depending on 
its level of activation, can either promote or inhibit podosome 
formation. It is possible that although the level of Rho-GTP 
  remains unchanged in Src-transformed cells, Rho may be cycling 
more rapidly between the active and inactive states. Another 
possibility is that Src may promote Rho-GTP loading and GTP 
hydrolysis at different sites within the cell, leading to local Rho 
activation. Indeed, in Src-transformed cells, Rho activation ap-
pears to occur at podosomes (  Berdeaux et al., 2004  ). 
 There are several possible mechanisms by which Src induces 
Rho activation. Src has been shown to directly induce Rho acti-
vation through its ability to phosphorylate Rho GDP dissocia-
tion inhibitors (RhoGDIs;   DerMardirossian et al., 2006  ). This 
phosphorylation causes Rho to dissociate from RhoGDI, allowing 
it to translocate to the membrane. In addition, activation of Rho-
GEFs by Src may increase nucleotide exchange. In particular, 
the Rho-specifi  c GEF Tim, a Dbl family member, is autoinhibited 
by an N-terminal helical motif, and phosphorylation of this motif 
by Src, both in vitro and in vivo, relieves this autoinhibition 
(  Yohe et al., 2007  ). Src can also phosphorylate the Rho family 
GEFs Vav1 and Vav2 in vitro and is required for EGF-mediated 
activation of Vav2 (  Riteau et al., 2003  ;   Servitja et al., 2003  ; 
expressed in ERK5-FL cells expressing activated ts-UP1 (unpub-
lished data). We confi  rmed this result by affi  nity precipitation 
of Rho GAPs using a Rho(63L)-GST fusion protein (  Garcia-
Mata et al., 2006  ). We found that more RhoGAP7/DLC-1 was 
recovered from ERK5-FL cells expressing activated ts-v-Src 
than from ERK5   /    ts-v-Src cells (  Fig. 8 E  ). Expression 
of MEF2C-VP16 also caused the level of RhoGAP7/DLC-1 to in-
crease in ERK5   /    cells expressing activated ts-v-Src (  Fig. 8 E  ). 
Additionally, in the absence of v-Src expression, neither the 
ERK5   /    nor the ERK5-FL cells expressed detectable levels 
of RhoGAP7/DLC-1 (  Fig. 8 E  ), which indicates that its expression 
is a result of Src activation of ERK5. Next, we reexpressed 
RhoGAP7/DLC-1 in ERK5   /    ts-v-Src cells to determine if 
this was suffi  cient to restore podosome formation. We used a 
RhoGAP7/DLC-1  –  GFP fusion construct to monitor transfected 
cells. Expression of the RhoGAP7/DLC-1  –  GFP fusion protein 
induced the formation of podosomes in   >  50% of the ERK5   /   
ts-v-Src cells compared with  < 5% in cells expressing GFP alone 
(  Fig. 9, A and B  ). 
 To determine whether RhoGAP7/DLC-1 is required for podo-
some formation, we expressed a dominant-negative RhoGAP7/
DLC-1  –  GFP fusion protein containing the N-terminal SAM 
domain but lacking GAP activity and the C-terminal START 
domain (unpublished data;   Healy et al., 2008  ) in SrcY527F-
transformed NIH3T3 cells. Expression of the DN  –  DLC-1  –  GFP 
inhibited podosome formation and resulted in cellular round-
ing (  Fig. 9, C and D  ), which indicates that the hyperactivation 
of Rho that results from RhoGAP7/DLC-1 inhibition, like that 
resulting from ERK5-deficiency, induces a rounded cellular 
morphology and reduced invasive capacity. Similarly, the ex-
pression of DN  –  DLC-1 in ERK5-FL ts-v-Src  –  transformed cells 
reduced the number of cells that were able to form podosomes 
from 63% in cells expressing GFP alone to 22% (unpublished 
data), which confi  rms that RhoGAP7/DLC-1 is required for ERK5-
dependent podosome formation. We conclude that Src induces 
RhoGAP7/DLC-1 expression via the ERK5  –  MEF2C pathway 
and that this limits Rho-GTP loading, allowing for podosome 
formation and cellular invasion. 
  Discussion 
  In addition to inducing autonomous cell proliferation, transfor-
mation by activated Src causes a drastic reorganization of the 
actin cytoskeleton. This results in the disappearance of stress 
 fi bers and the formation of podosomes, dynamic adhesions 
that degrade the underlying ECM and promote cellular inva-
sion. Podosomes and the closely related structures known as 
  invadopodia have more recently been observed in epithelial 
cells and carcinoma-derived tumor cell lines and appear to con-
tribute to tumor cell invasion (  Abram et al., 2003  ;   Spinardi et al., 
2004  ). Src is a key regulator of podosome formation in vivo, 
MEF2C-VP16 were grown for 24 h at 40  °  C and then shifted to 37  °  C for an additional 24 h. Cells were lysed and Rho afﬁ  nity pull-down assays were 
performed as described in the legend for   Fig. 5  . (E) Rho-GAP afﬁ  nity binding assays were used to determine the abundance of RhoGAP7/DLC-1 in the cell 
lines indicated. All cell lines were grown at 40  °  C for 24 h and then shifted to 37  °  C for 24 h. Cell lysates of equal protein concentration were incubated with 
GST-Rho63L  –  bound glutathione  –  Sepharose beads for 1 h at 4  °  C. Pellets were resuspended in Laemmli buffer and RhoGAP7/DLC-1 levels were measured 
by immunoblot analysis (M designates the protein marker lane).     
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or indirectly by receptor tyrosine kinases (  Schiller, 2006  ), and 
some of these may also be regulated by Src. Finally Src down-
regulates the expression of the Cdk inhibitor p27Kip1, which 
  Stovall et al., 2004  ). However, Vav proteins induce GTP loading 
on both Rho and Rac (  Han et al., 1997  ;   Liu and Burridge, 2000 ; 
  Zeng et al., 2000  ). Many other Rho GEFs are activated directly 
  Figure 9.       RhoGAP7/DLC-1 is preferentially expressed in ERK5-FL ts-v-Src cells, and its overexpression in ERK5    /     ts-v-Src cells can restore podosome 
formation.   (A) ERK5    /     ts-v-Src cells were transfected with a GFP-expressing vector alone (left) or a vector encoding RhoGAP7/DLC-1  –  GFP fusion. Cells 
were plated onto glass coverslips and, 24 h later, ﬁ  xed and stained with rhodamine-phalloidin. Arrows indicate cells expressing fusion protein. (B) Shown 
is a graphical representation of the mean percentage of cells that had podosomes (  n   = 3). (C) Src527F cells were transfected with DN-DLC-1  –  GFP or GFP 
alone and plated onto glass coverslips. 24 h after plating, cells were ﬁ  xed and stained with rhodamine-phalloidin and DAPI. Arrows indicate cells express-
ing GFP or DN-DLC-1  –  GFP. All images were taken with a 63  ×   objective. Bars, 20   μ  m. (D) Shown is a graphical representation of the mean percentage of 
cells that contained podosomes (  n   = 3). Error bars represent SD.     1207  ERK5 AND PODOSOME FORMATION   • Schramp et al. 
mote the formation of phosphatidylinositol-4,5-bisphosphate, 
thereby modulating the activity of actin-binding proteins such 
as gelsolin and Wiskott-Aldrich syndrome protein (WASP) 
(  Chellaiah, 2006  ). It is possible that Rho may be playing a similar 
role in Src-transformed cells. 
  In summary, Src induces RhoGAP7/DLC-1 expression by 
activating the ERK5  –  MEF2C pathway and thereby limiting the 
extent of Rho activation. The activation of this pathway is re-
quired for generation of podosomes and the invasive phenotype 
associated with Src transformation. Src activity is elevated in 
some epithelial cancers, and the extent of activation correlates 
with metastatic ability (  Frame, 2002  ;   Yeatman, 2004  ). It remains 
to be determined whether the Src  –  ERK5  –  MEF2C pathway plays 
a role in invasion by human carcinoma cells. 
  Materials and methods 
  Reagents 
  Anti  –  phospho-ERK5, anti-ERK5, and anti-MLC were obtained from Sigma-
Aldrich; anti  –  phospho-ERK1/2 (E10) mAb, anti-ERK1/2, and anti  –  phospho-
MLC were obtained from Cell Signaling Technology; anti-phosphotyrosine 
mAb (4G10) and anti-cortactin mAb (4F11) were obtained from Milli-
pore; anti-Fra1, anti-GFP, anti-ROCK, anti-Rac1, anti-MEF2, anti-VP16, 
anti-CDC42, anti-myc (9E10), and anti-RhoA were obtained from Santa 
Cruz Biotechnology, Inc.; anti-GAPDH was obtained from Abcam; ROCK 
inhibitor Y27632 and blebbistatin were obtained from EMD; MEK inhib-
itors U0126 and PD 98,059 were obtained from Sigma-Aldrich; anti-
RhoGAP7/DLC-1 was obtained from BD Biosciences; and gelatin  –  Oregon 
green 488 conjugate, anti  –  mouse Alexa Fluor 488 conjugate, rhodamine-
phalloidin conjugates, and SlowFade reagent were obtained from Invit-
rogen. Anti-FISH/Tks5 was a gift from S. Courtneidge (the Burnham 
Institute for Medical Research, La Jolla, CA). pCAG-myc and pCAG-myc-p  -
160ROCK    3 (constitutively active) were gifts from S. Narumiya (Kyoto 
University Faculty of Medicine, Kyoto, Japan). pEGFP-N1  –  DLC-1 has been 
described previously (  Healy et al., 2008  ). pEGFP-N1-DN  –  DLC-1(1  –  638 
amino acids) was generated using the DLC-1 cDNA (from GenBank under 
accession no.   NM_006094  ) by PCR and subcloned into the BamHI site of 
pEGFP-N1 (BD Biosciences). 
has been shown to inhibit Rho activation by blocking its inter-
action with Rho GEFs (  Besson et al., 2004  ). It seems likely that 
phosphorylation of the RhoGDI, activation of Rho-GEFs, and 
down-regulation of p27Kip1 may all contribute to Src-induced 
Rho activation. 
  The phosphorylation of p190RhoGAP by Src represents 
one mechanism by which Src limits Rho activation. Here, we pre-
sent evidence for a Src  –  ERK5  –  MEF2C pathway that also limits 
Rho activation by inducing the expression of RhoGAP7/DLC-1. 
Src can activate the classical MAP kinases ERK1 and ERK2, and 
their downstream target, the transcription factor Fra-1, has been 
shown to regulate the invasiveness of breast cancer cells as well 
as colon carcinoma cells through its ability to regulate Rho sig-
naling (  Vial et al., 2003  ;   Belguise et al., 2005  ). However, in Src-
transformed cells, ERK1/2 activation is only transient, whereas 
the activation of ERK5 is constitutive. ERK5 defi  ciency led to 
hyperactivation of Rho, even though both ERK1/2 activation and 
Fra-1 induction were observed in ERK5   /    cells expressing 
v-Src. Thus, ERK5 rather than ERK1/2 appears to be the critical 
MAPK in limiting the extent of Rho activation. This effect is 
mediated, at least in part, by activation of MEF2-dependent tran-
scription. The MEF2 family of transcription factors comprises 
MEF2A, -B, -C, and -D, which can homo- and heterodimerize to 
induce gene expression (  Martin et al., 1994  ;   Black et al., 1996, 
1998  ). MEF2-dependent signaling was enhanced in ERK5 re-
expressing cells that also expressed v-Src, and the expression 
of MEF2C-VP16 limited Rho-GTP loading in ERK5   /    cells 
expressing v-Src. One major transcriptional target of the Src  –
 ERK5 – MEF2  pathway  is  RhoGAP7/DLC-1.  RhoGAP7/DLC-1 
was only induced in cells expressing v-Src; ERK5 reexpression 
was not suffi  cient to induce RhoGAP7/DLC-1 synthesis in the 
absence of v-Src expression. Collectively, these results indicate 
that one pathway that limits the extent of Rho activation in Src-
transformed cells is the ERK5- and MEF2-dependent induction 
of RhoGAP7/DLC-1. 
 In the absence of ERK5, v-Src – transformed cells are rounded, 
with strong cortical actin staining, and lack podosomes. Cell 
spreading and podosome formation could be restored by reexpres-
sion of ERK5, by expression of MEF2C-VP16 or RhoGAP7/
DLC-1, or by inhibition of ROCK-mediated actomyosin con-
tractility. Thus, the hyperactivation of Rho that results from 
ERK5 defi  ciency leads to increased actomyosin contractility, 
and it is this that is responsible for cell rounding and podosome 
loss. However, blocking Rho-mediated signaling by expression 
of a dominant-negative RhoA mutant or with the bacterial exo-
toxin C3 also prevents podosome formation in Src-transformed 
cells (  Fig. 7  ;   Berdeaux et al., 2004  ). One possible explanation 
is that Rho signaling through some effector other than ROCK 
is necessary for Src-induced podosome formation. There are 
interesting parallels with podosome formation in osteoclasts. 
Mice that are defi  cient in Src display osteopetrosis, a disease 
caused by the failure of osteoclasts to resorb bone (  Thomas 
et al., 1991  ). Recently, it was shown that in osteoclasts, podo-
some formation, structure, and dynamics are dependent on the 
activity of endogenous Src (  Destaing et al., 2008  ). Osteoclast 
podosome formation is dependent on Rho function, and there is 
evidence that one of the roles of Rho in this system is to pro-
  Figure 10.       Src activates pathways that lead to Rho-GTP loading and 
Rho-GTP hydrolysis.   Rho regulation is a key intermediate in podosome 
formation. Src utilizes distinct pathways to both activate and inhibit Rho. 
Hyperactivation of Rho can inhibit podosome formation by increasing 
  actomyosin contractility. However, an as yet unknown aspect of Rho func-
tion is required for podosome formation.     JCB • VOLUME 181 • NUMBER 7 • 2008  1208 
with degrading matrix, as deﬁ  ned by the ability to form at least one degra-
dation patch regardless of its size, and are represented as a percentage of 
the total cells counted. Migration and invasion assays were performed using 
BD Biocoat Control cell culture inserts (migration) or Matrigel invasion cham-
bers (invasion; BD Biosciences). 3.8   ×   10 
4   cells were plated onto inserts 
preincubated at 37  °  C with DME using DME supplemented with 10% FBS as 
a chemoattractant. 24 h later, the cells were removed from the upper surface 
by scrubbing and the inserts were removed. The inserts were then ﬁ  xed in 
4% PFA, permeabilized with PBS containing 0.2% TritonX-100, and mounted 
onto coverslips using SlowFade reagent plus DAPI. Cell nuclei were counted 
and represented as the percentage of ERK5    /     ts-v-Src cells counted in re-
lation to ERK5-FL ts-v-Src cells. Experiments were repeated four times. 
  GTPase pull-down assays 
  Biochemical afﬁ  nity precipitation assays to measure Rho(GTP), Rac(GTP), 
and CDC42(GTP) were performed essentially as described previously (  Ren 
and Schwartz, 2000  ). In brief, plasmids expressing GST  –  Rho-binding 
  domain (RBD) or GST  –  p21-binding domain (PBD) were transformed into 
DH5     cells (Invitrogen) and expression was induced with 1 mM isopropyl 
    -  D  -1-thiogalactopyranoside for 2 h at 37  °  C. GST fusion proteins were 
puriﬁ   ed in batch on glutathione  –  Sepharose 4B beads (GE Healthcare). 
Pull-down assays were performed with 30  –  60   μ  g of GST fusion protein 
and 500  –  800   μ  g of protein lysate per sample. Samples were incubated at 
4  °  C with rocking for 1 h followed by washing ﬁ  ve times with appropriate 
wash buffer for assays using GST-PBD or GST-RBD. Precipitated proteins were 
solubilized in SDS sample buffer and resolved by SDS-PAGE. All tubes, 
reagents, and rotors were prechilled on ice before use and all steps were 
performed in a cold room. 
  Rho GAP pull-down assays 
  Biochemical afﬁ   nity pull-down assays to measure Rho GAP abundance 
were performed essentially as described previously (  Garcia-Mata et al., 
2006  ). Rho63L-GST plasmid constructs were obtained from K. Burridge 
(University of North Carolina at Chapel Hill, Chapel Hill, NC). Plasmids 
expressing GST-Rho63L were transformed into DH5     cells (Invitrogen) and 
expression was induced with 1 mM isopropyl     -  D  -1-thiogalactopyranoside 
for 3 h at 37  °  C. GST fusion proteins were puriﬁ  ed in batch on glutathione  –
  Sepharose 4B beads (GE Healthcare). Pull-down assays were performed 
with 30  –  60   μ  g of GST-fusion protein and 800  –  1,500   μ  g of protein lysate 
per sample. Samples were incubated at 4  °  C with rocking for 1 h followed 
by washing ﬁ  ve times with lysis buffer. Precipitated proteins were then solu-
bilized in SDS sample buffer and resolved by SDS-PAGE. All tubes, re-
agents, and rotors were prechilled on ice before use and all steps were 
performed in a cold room. 
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  Transfection, lysate preparation, and immunoblotting 
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  Immobilon polyvinylidene ﬂ  uoride ﬁ  lters (Millipore). Blots were incubated 
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3% BSA. The blots were incubated with primary antibody overnight at 
4  °  C, followed by incubation with HRP-conjugated secondary antibodies 
(Millipore), and immunolabeled proteins were visualized with Western 
Lightning Chemiluminescence Reagent Plus (PerkinElmer). 
  Cell lines 
  All cell lines were maintained in DME with 10% FBS. ERK5    /     and ERK5-
reexpressing cells (ERK5-FL) were gifts from A. Winoto (University of Cali-
fornia, Berkeley, Berkeley, CA). NIH3T3 parental cells and NIH3T3 cells 
expressing SrcY527F were gifts from S. Courtneidge. ERK5    /     and 
ERK5-FL cells were transfected with pBabe-hygro-ts-UP1. Resistant pools 
were screened for Src expression by monitoring tyrosine-phosphorylated 
proteins via immunoblotting. To generate cells expressing constitutively 
  active MEF2C, ERK5    /     cells expressing ts-UP1 were stably transfected 
with either pCDNA3.1-zeo alone or with pCDNA3.1-zeo-MEF2C-VP16 
provided by E. Olson (The University of Texas Southwestern Medical Center 
at Dallas, Dallas, TX). Expression of MEF2C mutants was monitored in stable 
transfectants by immunoblotting. 
  Chloramphenicol acetyl-transferase (CAT) reporter assay 
  pE102 MEF2-2  ×  2 CAT reporter plasmid was obtained from E. Olson. CAT 
reporter assays were performed according to manufacturer  ’  s instructions 
for the CAT enzyme assay (Promega). Adherent cells were transfected with 
pE102MEF2  ×  2CAT and 10-fold less pEGFP to monitor transfection efﬁ  -
ciency. 48 h after transfection, cells were lysed, and aliquots containing 
equal amounts of protein were incubated with 25   μ  g n-butyryl CoA and 
0.2   μ  Ci [ 
14  C]chloramphenicol (PerkinElmer). Reactions were terminated 
with ethyl acetate, spin-dried in a vacuum centrifuge (Speed Vac; Savant), 
and resuspended in equal volumes of ethyl acetate. Aliquots were spotted 
onto ﬂ  exible TLC plates (Selecto Scientiﬁ  c, Inc.). Butyrylated and unbutyry-
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Amounts of butyryl-bound chloramphenicol were measured using Image-
Quant software (GE Healthcare). 
  Immunohistochemistry 
  For visualization of podosomes in cells transformed by ts-v-Src, cells were 
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FBS at 40  °  C for 24 h. Cells were then shifted down to the permissive tem-
perature or maintained at 40  °  C for 24 h. For visualization of podosome 
rosettes in SrcY527F-transformed NIH3T3 cells, cells were grown on glass 
coverslips for 24 h and treated with DMSO or MEK inhibitor for the indi-
cated time. Cells growing on glass coverslips were ﬁ  xed in PBS plus 4% PFA 
for 30 min at room temperature or overnight at 4  °  C, permeabilized in PBS 
containing 0.2% Triton X-100, and incubated for 30 min in PBS containing 
3% BSA and 2% normal goat serum. Samples were incubated with primary 
antibodies for 1 h at room temperature. Signals were developed using 
either Alexa Fluor 488 goat anti  –  rabbit or anti  –  mouse IgG for 1 h at room 
temperature. F-actin was stained using rhodamine-phalloidin for 30 min. 
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ages were collected with a 40  ×   NA 1.3 or 63  ×   NA 1.25 objectives (Carl 
Zeiss, Inc.) at room temperature using a 510 confocal laser scanning micro-
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line, and emissions were detected using a band-pass 505  –  550 ﬁ  lter before 
the photomultiplier tube. Rhodamine was excited by a helium neon laser us-
ing the 546-nm primary line, and emissions were detected by using a long-
pass 650 ﬁ  lter before the photomultiplier tube. Images were exported as TIF 
ﬁ  les for subsequent processing with Photoshop version 7 (Adobe). 
  In situ zymography and migration/invasion assays 
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